CAU Scholar's Space: Hwang, In Gyu

Detailed Information

Hwang, In Gyu (황인규)

의과대학 (의학부(임상-서울))

Research Area: 혈액종양내과, 폐암, 위암, 담도암, 빈혈, 의학교육

Tel 031-670-1403
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Chemotherapy:11||Survival:7||Gemcitabine:7||Oxaliplatin:6||Cisplatin:6||Gastric cancer:6||Stomach neoplasms:5||Colorectal cancer:4||Irinotecan:4||Drug therapy:3||Breakthrough pain:3||chemotherapy:3||Docetaxel:3||Immunohistochemistry:3||prognosis:3||Biliary tract cancer:3||Cancer:3||Elderly:3||ERCC1:2||rectal cancer:2||Opioid analgesics:2||Hiccup:2||Histology:2||Risk factor:2||Overall survival:2||Paclitaxel:2||Capecitabine:2||Ifosfamide:2||Marginal zone:2||Secondline:2||돌발성 통증:2||Secondline chemotherapy:2||Colon cancer:2||Phase II:2||Adjuvant therapy:2||gastric cancer:2||5fluorouracil:2||Methylprednisolone:2||Platinum:2||Biomarkers:2||Adjuvant chemotherapy:2||Chemoradiotherapy:2||Prognosis:2||Prognostic:2||Dexamethasone:2||nonHodgkin lymphoma:2||Propensity score:2||Erlotinib:2||Neoplasms:2||R0 resection:2||Radiotherapy:2||Vascular endothelial growth factor:2||adjuvant chemotherapy:2||Clinical trial:2||ErbB2 receptor:1||Esophageal cancer:1||Ethnic groups:1||Ethnicity:1||Exercise:1||Expanded access program:1||Expert opinion:1||Extensivestage smallcell lung cancer:1||Fentanyl:1||Firstline:1||Fluorouracil:1||Frailty:1||GV1001:1||Gall bladder cancer:1||Gallbladder neoplasms:1||Gastrectomy:1||Gastrointestinal stromal tumor:1||Gastrointestinal stromal tumors:1||Geriatric assessment:1||Head and neck cancer:1||Head and neck neoplasms:1||Head and neck squamous carcinoma:1||Health knowledge:1||Hemophagocytic syndrome:1||Hepatitis:1||Hepatitis B virus:1||Hepatocellular carcinoma:1||Hyperprogressive disease:1||Imatinib:1||Immune cell:1||Immune check point:1||Immune checkpoint inhibitors:1||Immunecheckpoint inhibitors:1||Impact:1||Insitu hybridization:1||Incidence:1||Interstitial lung diseases:1||Intestinal:1||Intrahepatic cholangiocarcinoma:1||Intrathecal chemotherapy:1||Intubation:1||KG7:1||KIT amplification:1||KIT mutation:1||L1:1||Leptomeningeal:1||Liposarcoma:1||Lung cancer:1||Lymphomaassociated hemophagocytic syndrome:1||MLH1:1||MRNA expression:1||MSH2:1||Marginal zone Bcell lymphoma of MALT type:1||Melanoma:1||Mental Health Status:1||Merkel cell carcinoma:1||Mitomycin C:1||Modified FOLFIRINOX:1||Molecular targeted therapy:1||Mortality:1||Mucosaassociated lymphoid tissues:1||Multiple:1||NSCLC:1||Nasal cavity:1||Nasal mucosa:1||Neoaduvant concurrent chemoradiotherapy:1||Neuroendocrine tumors:1||Nextgeneration sequencing:1||Nilotinib:1||Nivolumab:1||Nonsmallcell lung carcinoma:1||Nonsmallcell lung cancer:1||Observation:1||Ointment:1||Opioids:1||Otolaryngology.:1||Pain:1||Palliative care:1||Pancreatic cancer:1||Pancreatic neoplasms:1||Paraneoplastic syndrome:1||Perihilar cholangiocarcinoma:1||Physical Activity Intensity:1||Physician practice patterns:1||Platinum refractory:1||Poly adenosine diphosphateribose polymerase 1 (PARP1):1||Polypharmacy:1||Position paper:1||Positron emission tomography:1||Postmarketing surveillance:1||Potentially inappropriate medication:1||Primary tumor location:1||Prognostic factor:1||Prospective:1||Pulmonary:1||Quality of life:1||Ramucirumab:1||Randomised controlled trial:1||Randomized trial:1||Realworld data:1||Recurrent and:1||Regorafenib:1||Renal cell carcinoma:1||Response rate:1||Retroperitoneal space:1||Retrospective analysis:1||S1:1||Salvage chemotherapy:1||Salvage regimen:1||Salvage treatment:1||Screening tools:1||Second line:1||Simvastatin:1||Skin:1||Skin cancer:1||Skin reaction:1||Small cell lung cancer:1||Smallcell lung cancer:1||Smallcell lung carcinoma:1||Squamous cell:1||Squamous cell carcinoma of the head and neck:1||Stomach neoplasm:1||Sum of target lesions:1||Survival analysis:1||Synthetic 3hydroxy3methyglutaryl coenzyme A (HMGCoA):1||TS1:1||Threeweek schedule:1||Time to progression:1||Transdermal patch:1||Trastuzumab:1||Ultrasound:1||Urinary bladder:1||Urothelial carcinoma:1||Uterine Mass:1||Uterine Metastases:1||Validation:1||XELIRI/FOLFIRI chemotherapy:1||adjuvant:1||atherosclerosis:1||best supportive care:1||biliary tract cancer:1||biomarker:1||bone marrow:1||breast cancer type 1 susceptibility protein:1||cancer:1||cancer vaccines:1||cell adhesion molecules:1||change management:1||chemosensitivity:1||chest pain:1||cisplatin:1||colorectal cancer:1||complex and mixed:1||coronary artery disease:1||dMMR:1||death:1||dosing:1||duration:1||efficacy:1||gastrectomy:1||gastrointestinal:1||gefitinib:1||geriatric medicine:1||heart:1||histopathology:1||hypertension:1||immune checkpoint inhibitor:1||intestine:1||intrinsic resistance:1||leucovorin (LV):1||lung:1||metastasis:1||mutation status:1||natural history:1||neuroendocrine tumors:1||nonsmall cell lung cancer:1||older adults:1||older patient:1||or metastatic:1||oxaliplatin:1||pemetrexed:1||physician:1||platinum agent:1||postoperative chemoradiotherapy:1||predictive:1||preoperative chemoradiotherapy:1||preoperative therapy:1||primary tumor location:1||radiation therapy:1||radiotherapy:1||renal cell carcinoma:1||risk management:1||sarcopenia:1||sedation:1||simvastatin:1||smoking:1||stomach:1||stomach neoplasms:1||sunitinib:1||timing:1||treatment patterns:1||tumor mutation burden  TMB:1||마약성 진통 약물:1||마약성 진통제:1||비소세포 폐암:1||신생물딸림증후군:1||암성 통증:1||완화의료:1||호산구증가증:1||5fluorouracil (5FU):1||Activin a:1||Acute kidney injury (AKI):1||Adenocarcinoma:1||Adjuvant chemoradiotherapy:1||Advanced biliary tract adenocarcinoma:1||Advanced gastric cancer:1||Advanced pancreatic carcinoma:1||Adverse event:1||Adverse reaction:1||Aged:1||Asian:1||Attenuated FOLFIRINOX:1||Autologous hematopoietic stem cell transplantation:1||B cell lymphoma:1||Bcell lymphoma:1||Biliary tract cancers:1||Biliary tract neoplasm:1||Biliary tract neoplasms:1||Biomarker enriched:1||Bladder cancer:1||Breast Cancer:1||Breast cancer type 1 and 2 susceptibility protein:1||CD2000R1:1||Cachexia:1||Cancer chemotherapy:1||Cancer pain:1||Carbonic anhydrase IX:1||Carcinoma, Esophageal neoplasm:1||Carcinomatosis:1||Cholangiocarcinoma:1||Choroid cancer:1||Colon:1||Colon Cancer:1||Colorectal neoplasm:1||Colorectal neoplasms:1||Corticosteroids:1||Cyclooxygenase2:1||DNA damage response:1||DNA damage response (DDR):1||Diagnostic criteria:1||Disseminated intravascular coagulation:1||Distal cholangiocarcinoma:1||Drugdrug interactions:1||Earlyonset gastric cancer:1||Efficacy:1||Emesis:1||Endometrium:1||Eosinophilia:1||Epidermal growth factor:1||Epidermal growth factor ointment:1||Epidermal growth factor receptor:1||Epistaxis:1||

STATISTICS: Total View :6,881,962; Today View :1,009

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE